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Abstract
The modification of protein and nanoparticle therapeutics with polyethylene glycol (PEG), a 
flexible, uncharged and highly hydrophilic polymer, is a widely adopted approach to reduce RES 
clearance, extend circulation time, and improve drug efficacy. Nevertheless, an emerging body of 
literature, generated by numerous research groups, demonstrates that the immune system can 
produce antibodies that specifically bind PEG, which can lead to the “accelerated blood clearance” 
of PEGylated therapeutics. In animals, anti-PEG immunity is typically robust but short-lived and 
consists of a predominantly anti-PEG IgM response. Rodent studies suggest that the induction of 
anti-PEG antibodies (α-PEG Abs) primarily occurs through a type 2 T-cell independent 
mechanism. Although anti-PEG immunity is less well-studied in humans, the presence of α-PEG 
Abs has been correlated with reduced efficacy of PEGylated therapeutics in clinical trials. The 
prevalence of anti-PEG IgG and reports of memory immune responses, as well as the existence of 
α-PEG Abs in healthy untreated individuals, suggests that the mechanism(s) and features of 
human anti-PEG immune responses may differ from those of animal models. Many questions, 
including the incidence rate of pre-existing α-PEG Abs and immunological mechanism(s) of α-
PEG Ab formation in humans, must be answered in order to fully address the potential 
complications of anti-PEG immunity.
Introduction
Extended circulation of proteins and nanoparticle therapeutics is often necessary to achieve 
adequate drug concentrations in target tissues.1–3 Unfortunately, many peptide and protein 
drugs are rapidly degraded and/or cleared from the systemic circulation due to their small 
size,4 and nanoparticulate drug carriers are readily eliminated by the cells of the 
mononuclear phagocyte system (MPS).3, 5 To overcome these challenges, proteins and 
nanoparticles are frequently conjugated to various hydrophilic polymers, which can 
significantly reduce degradation and opsonization, consequently extending the circulation 
half-lives of the modified therapeutics.1, 6 These polymers are frequently referred to as 
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“stealth” polymers, reflective of their ability to render proteins and particles inert to the 
biological environment.
Polyethylene glycol (PEG) has been, and continues to be, the most widely used stealth 
polymer in drug delivery, with over a dozen PEGylated pharmaceuticals currently on the 
market and many more in clinical testing.2, 3 PEG has a long history of safe use in humans, 
and the polymer is classified under the Generally Recognized As Safe (GRAS) category by 
the FDA. Despite the frequent use of PEG to extend circulation kinetics, a number of 
investigators have observed the rapid clearance of some PEGylated systems upon repeated 
administration.7, 8 This “accelerated blood clearance” phenomenon was ultimately attributed 
to the formation of PEG-specific antibodies.9 Indeed, animals that receive repeated doses of 
PEGylated systems often generate a potent IgM antibody response to PEG, which causes the 
complete elimination of subsequent doses of PEGylated agents from the circulation within 
minutes to a few hours.8 The induction of anti-PEG antibodies (α-PEG Abs) in humans was 
also observed in recent clinical trials of PEGylated proteins and has been correlated with 
poor drug efficacy. Interestingly, there is emerging evidence that α-PEG Abs can be found 
in the general population in individuals who likely have never received PEGylated 
therapeutics injected systemically.10, 11 As many more PEGylated protein and nanoparticle 
therapeutics are expected to enter the market over the next several years, an improved 
understanding of the prevalence, induction, and effects of anti-PEG immunity is 
undoubtedly critical for the continued clinical use of PEGylated systems.
ADVANTAGES AND PHYSICOCHEMICAL PROPERTIES OF EFFECTIVE 
STEALTH PEGYLATION
The stealth properties of PEG are rooted in several distinctive molecular and physical 
characteristics. First, PEG is exceedingly hydrophilic, with each ethylene glycol subunit (-
CH3-CH3-O-) surrounded by a minimum of 2–3 water molecules.12, 13 Thus, PEG coatings 
generate a hydration shell with a large excluded volume that sterically prevents 
biomacromolecules from penetrating into the polymer layer and binding to the underlying 
core via hydrophobic or electrostatic interactions.14–16 Second, PEG is highly flexible and 
exhibits high chain mobility, which results in an exceedingly large number of polymer chain 
conformations. As a result, any substantial reduction in the conformational freedom of PEG, 
including the displacement of PEG chains by intruding biomacromolecules, is 
thermodynamically unfavorable.17–19 Together, these features greatly suppress interactions 
between PEGylated systems and the biological environment.
For proteins, PEG conjugation decreases enzymatic degradation, opsonization, and 
immunogenicity of the protein core;4 PEGylation can also improve stability and solubility.2 
Additionally, the resulting increase in the hydrodynamic diameter can reduce renal 
elimination and improve the biodistribution and pharmacokinetics of PEGylated proteins.4 
For nanocarriers, PEGylation reduces opsonization and MPS cell clearance, resulting in 
significantly prolonged circulation kinetics.5, 6 For oncological applications, this effect often 
leads to greater tumor distribution via the enhanced permeability and retention (EPR) effect, 
while decreasing accumulation in non-targeted organs.3 PEGylation can also improve 
nanocarrier stability and minimize the premature release of cargo therapeutics. Finally, PEG 
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coatings have been shown to decrease nanocarrier association with structural components of 
mucus and extracellular matrix, thereby improving distribution and delivery to regions such 
as mucosal surfaces and brain tissues.20, 21
Naturally, the effectiveness of PEG as a nanoparticle coating polymer is critically dependent 
on the density and resulting conformations assumed by conjugated PEG chains. The 
thickness of the PEG coating is dictated by its Flory radius (RF; a function of the molecular 
weight) and the distance between two neighboring PEG chains (D; a function of the PEG 
coating density).22 When neighboring PEG chains are sparsely packed and do not overlap, 
PEG occupies a diffuse volume generally termed a “mushroom” conformation (RF/D ≤ 1). 
As more PEG polymers are introduced, the excluded volume and repulsion by neighboring 
PEG chains cause the polymer to transition from a diffuse conformation to a more extended 
“brush” conformation (RF/D > 1),3, 23 eventually reaching a “dense brush” regime, where 
the height of the PEG layer exceeds the RF by at least two-fold (at RF/D > 2.8) (Fig. 
1A).18, 24, 25 The mushroom/brush transition has long been considered to be the critical 
threshold at which PEG begins to exhibit stealth polymer functions. However, we and others 
have recently found that both rigid polymeric and metallic nanoparticles require PEG 
grafting densities far exceeding the minimum for brush conformation to demonstrate 
effective stealth nanoparticle behavior.25, 26 Indeed, maximal reduction of uptake by mouse 
and human phagocytes in vitro required at least a dense brush PEG coating (Fig. 1B and D), 
and PEG grafting densities extending well into the dense brush conformation were necessary 
for the evasion of serum protein adsorption (Fig. 1C), as well as to achieve sustained 
circulation in vivo (Fig. 1E).
PEG-SPECIFIC IMMUNITY IN ANIMAL MODELS
The first report of α-PEG Abs in vivo
Because proteins are generally excluded from densely PEG-coated surfaces, it is convenient 
and intuitive to assume that PEG should be immunologically inert and escape binding by 
antibodies. However, in 1983, less than a decade after the introduction of protein 
PEGylation, Richter and Akerblom reported the generation of PEG-specific antibodies 
following intramuscular (i.m.) or subcutaneous (s.c.) injections of various PEG-modified 
proteins in Complete Freund’s Adjuvant.27 In contrast, they found that free PEG (MW 
10-5.9 x 103 kDa) administered under similar conditions exhibited little to no 
immunogenicity. This landmark study demonstrated for the first time that antibodies can be 
formed against PEG polymers. Later studies confirmed that not only can α-PEG Abs be 
elicited by immunization with PEGylated proteins,28, 29 but also that the induction of PEG-
specific immunity can occur in the absence of adjuvants.30, 31
Accelerated blood clearance of PEGylated systems is attributed to α-PEG Abs
While single doses of PEGylated therapeutics often demonstrate extended system circulation 
times in vivo, some PEGylated systems exhibit rapid elimination upon repeated 
administration. For example, Moghimi and Gray reported in 1997 that when long-circulating 
polystyrene particles coated with poloxamine 908 (a PEG-containing surfactant) were 
administered 3–4 days after an initial dose, the particles were swiftly cleared from systemic 
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circulation by MPS cells in rats.32 Similarly, Dams et al. and several other groups observed 
that repeated weekly dosing of empty PEG liposomes also significantly reduced the 
circulating half-lives of the subsequent doses (Fig. 2A), with a corresponding increase in 
liver accumulation and hepatic clearance (Fig. 2B), as well as moderate increases in splenic 
accumulation (Table 1).7, 33–36 This unexpected effect was termed the “accelerated blood 
clearance” (ABC) phenomenon, and the biological factors underlying the phenomenon 
remained unclear for a number of years after its discovery. Because the infusion of “naïve” 
mice with plasma from animals pre-dosed with poloxamine-coated polystyrene beads failed 
to generate an ABC effect, Moghimi and Gray suggested that the observed phenomenon was 
not due to plasma factors but rather potentially resulted from an change in phagocyte 
receptor expression and/or activity elicited by the initial particle dose.32 In contrast, Dams et 
al. reported that the transfusion of blood or serum from rats pre-treated with PEGylated 
liposomes generated an ABC effect and observed that this effect was dependent on the 
presence of a heat-labile, 150-kDa serum factor. Because ABC was observed for serum 
depleted of IgG or IgM, they proposed that the observed effect was likely due to 
complement protein(s).7 However, because the extent of IgM depletion appeared 
incomplete, the involvement of residual IgM could not be discounted. Although Laverman 
et al. did not identify the specific immune factors responsible, they observed that the ABC 
phenomenon occurs in two phases: the induction phase, when the immune system is primed 
by the initial injection, and the effectuation phase, when the pharmacokinetics and 
biodistribution of the PEGylated therapeutics are affected by the resulting immune 
response.36
Since then, mounting and irrefutable evidence has established that α-PEG Abs can be 
elicited by PEGylated systems and is likely responsible for the observed ABC that can 
greatly alter the pharmacokinetics and efficacy of PEGylated therapeutics in vivo. Ishida et 
al. first observed that the serum of pre-treated rats, as compared to naïve animals, 
demonstrated greater antibody adsorption onto PEGylated liposomes, suggesting that 
antibodies were the dominant serum factor responsible for the ABC effect.37, 38 Soon 
afterwards, the same group reported that intravenous injection of PEGylated liposomes 
strongly induced the production of PEG-specific antibodies (Fig. 2C),39 and the presence of 
these antibodies was correlated with hepatic clearance.9 Cheng et al. demonstrated that the 
injection of monoclonal α-PEG IgM into naïve mice resulted in the rapid clearance of 
PEGylated therapeutic proteins (e.g., 38-fold reduction in systemic concentration compared 
to uninjected control).31, 40 Numerous other groups have subsequently corroborated the 
relationship between α-PEG Abs and the ABC phenomenon.41–46 The observed α-PEG Ab 
response is predominantly IgM,9, 45, 47, 48 although the development of anti-PEG IgG has 
also been reported (Fig. 2C and D, Table 1).29, 41, 49 α-PEG Ab-mediated complement 
activation may also be involved in the MPS clearance of repeatedly dosed PEGylated 
therapeutics. Antibodies, particularly IgM, can efficiently activate the complement system, 
and opsonization by complement proteins such as C3b facilitates particle phagocytosis and 
clearance. Serum from rats generating an ABC response demonstrated complement 
activation upon incubation with PEGylated liposomes,50 and heat-treatment (complement 
inactivation) of this serum abrogated the first-pass hepatic clearance of PEGylated 
liposomes.51 A proteomics analysis indicated that, after the induction of α-PEG Abs, 
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PEGylated liposomes are predominantly bound by plasma IgM and complement proteins 
(i.e., C1, C3) in mice.52 Additionally, complement proteins can disrupt liposomal 
membranes; indeed, the leakage of cargo epirubicin from PEG-liposomes was associated 
with complement activation.53 Altogether, these results suggest that complement can play an 
important role in the ABC of PEGylated liposomes, although the role of complement in the 
ABC of various non-liposomal PEGylated systems (e.g., polymeric nanoparticles, proteins) 
remains to be further investigated.
The development of α-PEG Abs and its resulting effects on clearance has been reported not 
only in a variety of animal models, ranging from rodents, rabbits, and canines to non-human 
primates,7, 28, 46, 54 but also for different classes of PEGylated systems, including polymeric 
nanoparticles, micelles, adenovirus, and proteins (Table 1).30, 44, 55 Across fifteen studies, 
the presence of α-PEG Abs reduced the circulation half-lives of PEGylated agents by 2- to 
10-fold on average and increased the hepatic and splenic accumulation by roughly 2- to 5-
fold and 1- to 2-fold, respectively. These results clearly underscore the potency and impact 
of anti-PEG immunity, which represents a particularly important concern in light of 
increasing number of PEGylated therapeutic proteins and nanomedicines that are FDA-
approved or currently in clinical development. Indeed, recent FDA guidelines recommend 
screening for α-PEG Abs when evaluating the potential immunogenicity of therapeutic 
proteins.56
Immunological mechanism(s) of α-PEG Ab induction
Given PEG’s well-documented anti-fouling properties, the induction of PEG-specific 
antibodies no doubt appears paradoxical, and the precise mechanism(s) underlying the 
formation of α-PEG Abs has received much attention. To date, research efforts have 
primarily focused on elucidating the cellular processes involved in the generation of PEG-
specific immunity in rodent models after repeated intravenous (i.v.) dosing of PEGylated 
liposomes.
In both rats and mice, splenectomy prior to or immediately following the injection of an 
initial dose of PEGylated liposomes dramatically reduced the extent of anti-PEG IgM 
responses, whereas splenectomy performed 4 or more days after the initial injection did not 
eliminate the ABC of PEGylated systems, suggesting that splenic cells serve as the primary 
site of α-PEG Ab induction.30, 37, 48, 57 In addition, the ABC phenomenon appears to 
involve B cells functioning through T-cell independent (TI) mechanisms, as T cell-deficient 
nude mice, but not SCID mice (B and T cell-deficient), generated an ABC response to both 
empty and nucleic acid-containing PEGylated liposomes.48, 57, 58 In general, marginal zone 
B cells are involved in immune responses to TI antigens.59 Consistent with a TI response to 
PEG, splenic marginal zone B cell depletion in rats eliminated the formation of PEG-
specific IgM antibodies, and PEGylated liposomes are initially localized in the marginal 
zone upon repeat injection.60
Due to PEG’s structural similarity to other highly repetitive polymeric antigens such as 
microbial polysaccharides, the research groups of Kiwada and Ishida have explored the 
possibility of a type 2 T-cell independent (TI-2) mechanism (Fig. 3).8, 59 In this proposed 
mechanism, the initial dose of a PEGylated therapeutic first enters the spleen, where it 
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comes in contact with marginal zone B cells and crosslinks surface antibodies present on 
these cells, triggering the production of PEG-specific IgM antibodies. Then, the induced 
anti-PEG IgM binds to subsequent doses of PEGylated agents in the circulation and 
activates complement binding, ultimately resulting in hepatic clearance through Kupffer cell 
uptake.8
While the majority of published findings on the induction of α-PEG are consistent with this 
TI-2 mechanism, there are a small number of studies that present contrasting results. TI 
responses typically do not induce significant memory or antibody class switching unless 
there is strong co-stimulation by non-cognate immune cells and/or secreted factors such as 
cytokines (e.g., IL-1, IL-6, TNFα).61–63 While IgM is indeed the dominant α-PEG Ab 
isotype observed, a few studies have reported anti-PEG IgG responses.29, 41, 49 For example, 
Judge et al. observed a strong initial IgM response that was replaced by an elevated IgG 
response (peaks at day 7 and 20, respectively) after a single dose of PEGylated liposomes 
(Fig. 2D).41 Whether PEG-specific IgG was formed due to exceptional B cell stimulation 
that generated class switching or to the induction of α-PEG Abs through non-TI-2 
mechanisms remains unclear. The ABC phenomenon was also elicited after the s.c. injection 
of PEGylated solid nanoparticles, leading Zhao et al. to suggest that regional lymph nodes 
can also directly produce anti-PEG immune responses.64 However, because a minor amount 
of the s.c. administered nanoparticles were distributed to the spleen, the involvement of 
splenic lymphocytes cannot be excluded. Additionally, macrophage depletion prior to an 
initial dose of PEGylated liposomes completely abrogated the ABC of subsequent doses of 
PEGylated liposomes in rats, suggesting the potential dependence of α-PEG Ab induction 
on non-B cell populations as well.36
Reflective of the immunological pathway(s) responsible for the formation of anti-PEG 
immunity, there are also substantial variations reported for the formation of long-term 
memory responses. In many studies, the ABC effect is generated 3–7 days after the initial 
dose (Fig. 2A and B) and diminishes over the period of a couple weeks.43, 48 Nevertheless, 
Semple et al. did report an anti-PEG IgM response that persisted for at least 50 days in dogs 
(1, 2, 3, or 7 d dosing intervals), highlighting the potential for long-term ABC responses in 
vivo and the need to further evaluate not only acute but also long-term α-PEG Ab 
responses.57
Properties of the α-PEG Ab epitope
How α-PEG Abs specifically bind to PEG polymers remains a mystery, as is the antigenic 
determinant that leads to α-PEG Ab responses. As noted above, TI-2 antigens are typically 
composed of identical, repeating epitopes that crosslink B cell receptors to generate 
significant and prolonged activation of B cells without co-stimulation by T cells.8, 59 The 
typical PEG chain lengths for modified nanoparticles and proteins are approximately 1–5 
kDa and 5–40 kDa, respectively, which covers a range from several tens to hundreds of 
ethylene glycol subunits and could readily and extensively crosslink any receptors capable 
of binding PEG. Richter and Akerblom reported hapten inhibition of α-PEG Ab 
precipitation with PEG of 300 MW, suggesting that the antigenic epitope of PEG may 
consist of a 6–7 subunit region.27 This value has been commonly cited as the size of the α-
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PEG Ab binding epitope. Nevertheless, a recent study observed that tri(ethylene glycol) 
(MW 150–160) was bound by α-PEG Abs in direct and competitive ELISAs (see Sidebar 1 
for methods of α-PEG Ab detection).65 We have likewise found that both anti-PEG IgM and 
IgG can bind to polymers composed of repeating methacrylate PEG300 subunits 
(unpublished observations, Yang and Lai). Together, these findings suggest that the α-PEG 
Ab binding epitope could be smaller than the proposed 6–7 subunit length.
Sidebar
Detection of α-PEG Abs by validated ELISA methods
α-PEG Abs have been detected in animal models and humans using a variety of methods, 
including passive hemagglutination, immunodiffusion, flow cytometry, Western blotting, 
and enzyme-linked immunosorbent assays (ELISAs).27, 41, 49, 82 Of these methods, 
ELISAs can simultaneously provide high sensitivity, rapid screening of multiple samples, 
and antibody isotype/subclass detection. As a result, most recent studies have used 
ELISAs almost exclusively to analyze α-PEG Ab responses. However, for many reports 
of α-PEG Abs, particularly those using animal models, antibody specificity to the PEG 
moiety was not always thoroughly confirmed. Indeed, most in vivo studies of treated 
animals only performed direct ELISAs using plates coated with the same PEGylated 
material (e.g., PEG-lipid) that was injected; thus the possibility that induced antibodies 
were actually bound to the carrier rather than PEG itself cannot be fully discounted.
As noted by others, there is a critical need for more rigorous, validated α-PEG Ab 
detection methods.11, 66 In our opinion, both direct and competitive ELISAs should be 
used in combination to confirm the PEG-specificity of α-PEG Abs with the application 
of proper controls and conditions (see Fig. 5), as was carried out in some recent human 
trials.75, 81, 86 Standard curves can be generated using commercially available α-PEG 
Abs (e.g., mouse, rat, rabbit, chicken, goat, and monkey host Abs) to quantify induced or 
pre-existing α-PEG Abs. Additionally, the validation of ELISA protocols (e.g., 
determination of precision, sensitivity, reagent interference) must be performed and 
reported.81, 86 Importantly, the use of Tween and other PEG-containing detergents must 
be avoided, as they can significantly reduce the sensitivity of α-PEG Ab detection 
assays.28 The development of standardized laboratory tests that can quantitatively and 
accurately measure α-PEG Ab levels is crucial to furthering our understanding of anti-
PEG immunity.
Since free PEG is known to be non-immunogenic, the antigenic determinant for α-PEG Abs 
has been suggested to occur at the linkage between PEG and other materials. Based on the 
observations that α-PEG Abs induced by hydrophobic PEGylated micelles were able to bind 
to PEGylated liposomes, and vice versa, whereas hydrophilic PEGylated micelles avoided 
the induction of and opsonization by α-PEG Abs, Shiraishi et al. proposed that the α-PEG 
Ab epitope is the interphase between a hydrophobic core and conjugated PEG groups.45 
Nevertheless, because free PEG can inhibit α-PEG Ab binding in competitive ELISAs and 
hemagglutination assays,27, 28 at least some of the observed α-PEG Ab responses must be 
specific to PEG itself. Due to the disparity in the immune responses to free PEG versus 
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PEGylated therapeutics, as well as the frequent immunogenicity of therapeutic agents that 
require PEGylation, PEG has been proposed to function as a hapten (i.e., a molecule that 
elicits immune responses only when conjugated to a carrier agent).10, 66
Factors influencing the formation of anti-PEG immunity and ABC in animals
The ABC phenomenon and immune responses to PEG are affected by a number of factors 
such as the dosing regimen,43 animal model,54 drug/cargo incorporation,67 nanocarrier/
protein identity and composition,27, 35 and PEG structure.30, 68 For example, the dosing 
interval that generates a maximal ABC response is dependent on the timing for α-PEG Ab 
formation, which typically peaks at 3–7 days post-injection (Fig. 2A and B). Additional 
doses administered after less than 48 h or more than 4 weeks typically exhibit extended 
circulation times comparable to the initial dose.69, 70 High doses of PEGylated therapeutics 
can also influence α-PEG Ab formation, likely due to the induction of immune tolerance or 
B cell anergy.9, 38 Encapsulated drug cargo can also play a key role in PEG-specific immune 
responses to PEGylated nanocarriers. For example, the incorporation of immunostimulatory 
substances such as CpG DNA enhances α-PEG Ab responses,71 while the loading of 
cytotoxic chemotherapeutics can directly suppress α-PEG Ab induction,36, 72, 73 likely 
through the direct killing or impaired proliferation of B cells. Additionally, the presence of 
endotoxins, which can elicit strong inflammatory responses, may have potentially affected 
the immunogenicity of the administered PEGylated agents; however, only a small number of 
studies reported testing for endotoxin contaminants.32, 41, 57 The composition and 
physicochemical properties (e.g., size,44, 74 lipid membrane rigidity,54 curvature, PEG 
density and terminal groups28, 30, 42) of PEGylated systems can also affect α-PEG Ab 
induction and ABC responses. For an excellent review of these various factors, please refer 
to Ref 8.
ANTI-PEG IMMUNITY IN HUMANS
PEGylation has been critical to the success of numerous therapeutic agents currently on the 
market, including uricase, interferon-α, and liposomal doxorubicin, as well as many protein 
and nanomedicines currently drugs in clinical trials.4, 75, 76 However, a growing body of 
evidence clearly suggests that the induction of α-PEG Abs is possible in humans. In contrast 
to most animal studies, the α-PEG Ab response in humans is more skewed towards IgG 
isotype antibodies (Table 2). Interestingly, we and others have found that a significant 
fraction of the normal population actually possesses pre-existing α-PEG (i.e., the presence 
of PEG-specific antibodies in the absence of treatment with PEGylated therapeutics), which 
may become even more prevalent in the years ahead.77 Both pre-existing and induced α-
PEG Abs present significant challenges to the clinical efficacy of PEGylated 
therapeutics.10, 11
Pre-existing α-PEG Abs in the general population
In 1984, Richter and Akerblom first observed that 0.2% and 3.3% of normal subjects and 
untreated allergy patients, respectively, exhibited relatively high titers of mostly anti-PEG 
IgM (Table 2).78 Almost 20 years later, Armstrong et al. reported a much higher incidence 
rate of 27–28% among normal healthy subjects.11 Interestingly, they observed 
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predominantly PEG-specific IgG, with 19%, 5%, and 3% of the total individuals possessing 
IgG only, IgM only, and both IgM and IgG antibodies, respectively. The reasons for the 
discrepancy in the observed α-PEG Ab incidence rates are unclear. Both studies utilized 
passive hemagglutination of PEG-modified RBCs to detect PEG-specific antibodies, so the 
differences are unlikely to be caused by the method of detection. In light of the decades-long 
gap between the reports, these variations could reflect a substantial increase in the 
prevalence of pre-existing α-PEG Abs in the general population, but this hypothesis has not 
been carefully assessed.
How pre-existing α-PEG are generated in individuals who have never received any formal 
treatment with PEGylated therapeutics remains largely unknown. As a GRAS product, PEG 
is widely used in cosmetics, processed foods, pharmaceuticals, agriculture, and industrial 
manufacturing. PEG-containing surfactants, as well as PEG itself, are found in the vast 
majority of household and hygiene products (e.g., soap, shampoo, toothpaste, lotion, 
detergent). It is natural to assume that frequent exposure to PEG could lead to the inevitable 
formation of α-PEG Abs, but this constant exposure does not offer insight into the actual 
mechanism(s) underlying anti-PEG immunity. While we have no direct supportive evidence 
to date, we wish to offer the following speculation: the human body is frequently subjected 
to insults (e.g., abrasions, lacerations, skin tears) that may result in local inflammatory 
responses and recruitment of immune cells. Due to the ubiquitous presence of PEG in 
products used in daily life, as well as in many disinfecting agents (e.g., soaps and detergents 
used to clean wounds), PEG is likely present at or introduced to sites of inflammation. The 
presence of PEG in close proximity to highly active immune cells, particularly in an 
immunostimulatory environment containing microbes and/or bactericidal chemicals, may be 
sufficient to drive the induction of α-PEG Abs. Subsequent persistent exposure to PEG-
containing products may further induce a robust memory immune response to the polymer.
Beyond the initial reports by Richter and Akerblom and by Armstrong et al., the prevalence 
of pre-existing α-PEG Abs has been further reported in both healthy donors and untreated 
controls of clinical trials (Table 2). Tillmann et al. observed an incidence rate of 7%–8% in 
healthy individuals and in hepatitis and lupus patients, whereas 44% of hepatitis C patients 
were found to be positive for α-PEG Abs prior to treatment with PEGylated interferon.79 
Treatment-naïve gout patients and patients with phenylketonuria demonstrated pre-existing 
α-PEG Ab incidence rates of 19% and 16%, respectively.80, 81 In addition, 38% of pediatric 
leukemia patients receiving unmodified asparaginase were also found to possess α-PEG 
Abs.82 Importantly, the relatively high incidence rate in this study was observed for patients 
with a mean age of 8.8 years, suggesting that α-PEG Abs can be developed relatively early 
in life. In a pilot study, we observed that α-PEG Abs were present in 42% (13/31) of healthy 
adult individuals, with 26%, 3%, and 13% of the total individuals exhibiting IgG only, IgM 
only, and both IgM and IgG antibodies, respectively (unpublished observations, Yang and 
Lai).
Induction and effects of α-PEG Abs in individuals treated with PEGylated therapeutics
Studies of PEGylated therapeutics in humans began nearly three decades ago, but early 
results indicated that α-PEG Ab responses were non-existent or clinically insignificant in 
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humans. In a clinical trial of PEG-modified allergens, 50% of allergy patients had high α-
PEG Ab titers after one year of hyposensitization treatment, compared to 3.3% of untreated 
patients.78 However, the occurrence of α-PEG Abs did not appear to prime further immune 
responses, as the α-PEG Ab incidence rate decreased to 28.5% in patients receiving two 
years of treatment. The potential effect of α-PEG Abs on the efficacy of hyposensitization 
treatment or adverse effects was not examined. Ten of seventeen patients (59%) treated with 
PEG-modified bovine adenosine deaminase (PEG-ADA, Adagen) generated IgG anti-PEG-
ADA antibodies, but competitive ELISAs using ADA and different PEGylated proteins 
indicated that these antibodies were formed against ADA rather than the PEG moiety.83 In a 
study of hepatitis C (HCV) patients, the presence of pre-existing α-PEG Abs in 44% of the 
patients did not appear to affect the efficacy of antiviral PEG-interferon therapy.79 The 
potential reasons for the apparent lack of α-PEG Ab effects, including immune impairment 
and hepatic damage caused by HCV, were not explored.
Unlike most studies that report α-PEG Ab responses in only a subset of patients, 100% of 
phenylketonuria patients developed PEG-specific Abs within 6 weeks of a s.c. injection of 
PEGylated phenylalanine ammonia lyase (PEG-PAL).80 Although the authors found that 
neither pre-existing nor induced α-PEG Abs appeared to influence the efficacy of a single 
dose of PEG-PAL, peak therapeutic efficacy was observed on day 6, whereas testing for α-
PEG Abs was performed on days 0, 14, 28, and 42. Thus, the potential effects of the 
observed α-PEG responses on the activity of multiply-dosed PEG-PAL is unclear. 
Importantly, two patients in the study later experienced severe adverse reactions to i.m. 
injections of medroxyprogesterone acetate, which contains both free PEG and polysorbate as 
excipients. While there is insufficient data to prove causation or statistical significance, this 
observation indicates that future studies should also investigate whether α-PEG responses 
may impact not only the repeated administration of PEGylated therapeutics but also the use 
of pharmaceutical formulations comprising free PEG or PEG-containing chemicals 
excipients.
The correlation between the presence of α-PEG Abs and reduced therapeutic efficacy of 
PEGylated drugs has been observed for only two PEG-modified proteins to date: PEG-
asparaginase (PEG-ASNase) and PEG-urate oxidase (PEG-uricase, pegloticase) (Table 2). 
In pediatric acute lymphoblastic leukemia patients treated with PEG-ASNase, anti-PEG IgM 
antibodies were observed in 46% of the patients, and the presence of α-PEG Abs was 
strongly correlated with the rapid clearance of PEG-ASNase and loss of protein activity 
(Fig. 4A).82 In contrast, α-PEG Abs present in patients treated with unmodified ASNase 
exhibited no effect on therapeutic protein clearance or activity (Fig. 4B). Because serum 
samples were only collected after treatment, it is not clear whether the observed α-PEG Abs 
were induced or pre-existing. However, given that 38% of patients treated with control 
ASNase also exhibited α-PEG Abs, the authors suggested that the antibodies observed in the 
PEG-ASNase group were likely pre-existing.
In the earliest clinical trial of PEG-uricase, 38% of refractory gout patients developed α-
PEG Abs, which was correlated with poor efficacy, after a single s.c. injection of the 
PEGylated drug.75 This PEG-specific antibody response demonstrated apparent class 
switching, with IgM and IgG predominating at days 3–7 and 7–14, respectively, after 
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injection. One patient was later re-challenged with PEG-uricase and demonstrated an 
anamnestic antibody response to the PEGylated protein.75 In a separate study, α-PEG Ab 
responses were generated in 35% of gout patients after a single i.v. infusion of PEG-uricase, 
and α-PEG Ab formation also associated with rapid protein clearance.84 Additionally, one 
patient with a pre-existing α-PEG Ab response exhibited a correspondingly reduced half-life 
for PEG-uricase.
Repeated dosing of PEG-uricase generated two distinct patient populations: responders 
(sustained low plasma uric acid levels) and non-responders (early decrease in plasma uric 
acid levels followed by a rebound to baseline levels) (Fig. 4C).85, 86 The production of high 
titer anti-PEG-uricase antibodies, most of which appeared to be specific to PEG (Fig. 4D), 
was correlated with the loss of PEG-uricase activity.86 Similar results were obtained in a 
study by Hershfield et al., with 37% of treatment-naïve patients establishing an α-PEG Ab 
response and non-responsive to PEG-uricase treatment by the end of the clinical trial; half of 
these α-PEG Ab responses were pre-existing.81 Three patients that received PEG-uricase 
during previous studies (1–3 years prior) were also non-responsive to the new round of 
treatment, exhibiting loss of PEG-uricase efficacy earlier than the affected treatment-naïve 
patients (2–7 days vs. ~2 weeks). Interestingly, of the demographic characteristics (e.g., age, 
gender, BMI, renal function) examined during the repeated dosing studies, only age (>60–70 
years) and organ recipient status, both of which involve some level of immunoinsufficiency, 
were found to be associated with reduced α-PEG Ab formation.81, 86 In addition to rapid 
PEG-uricase clearance, α-PEG Ab-positive individuals also demonstrated an increased rate 
of infusion reactions,75, 81, 85 but the precise involvement of α-PEG Abs in adverse 
reactions to PEG-uricase and other PEGylated therapeutics remains unclear.66
Clinical implications of and strategies to overcome α-PEG Abs
The reduced efficacy of PEG-ASNase and PEG-uricase in the presence of α-PEG Abs 
highlights the potential impact of PEG-specific immune responses on the growing clinical 
use of PEGylated therapeutics and underscores the need to incorporate testing for α-PEG 
Abs in clinical trials of PEG-containing drugs. Standard laboratory tests (see Sidebar 1) that 
can quantitatively and accurately measure α-PEG Ab levels and determine a patient’s α-
PEG Ab status are crucial to this effort, as suggested by others.11, 66, 87 Importantly, clinical 
trial designs must screen for pre-existing anti-PEG immunity, as well as monitor treatment 
history, since previous exposure to PEGylated therapeutics could prime future responses to 
subsequent therapy with PEGylated drugs. Furthermore, the true extent of α-PEG Abs in the 
human population and the factors that lead to α-PEG Ab immunity must be further 
investigated.
In addition to an improved understanding of the prevalence and development of anti-PEG 
immunity in humans, strategies to avert or overcome α-PEG Ab responses must be 
developed. Unfortunately, the effect of important dosing regimen factors identified in animal 
studies remains to be fully evaluated in human subjects. In the clinical trials of PEG-uricase, 
neither the dose (0.5–24 mg/patient), dosing interval (2–4 weeks), nor route of 
administration (s.c. or i.v.) appeared to affect α-PEG Ab induction or its effects,75, 81, 86 but 
these results must be corroborated for other PEGylated drugs. The use of cleavable or 
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sheddable PEG has been demonstrated to decrease or eliminate α-PEG Ab and ABC 
responses in vivo,41, 57, 88 but the rapid loss of the stealth PEG coating also significantly 
reduces the circulation half-life and may render the modified therapeutics ineffective. As 
was observed for a small number of organ transplant recipients, co-treatment with 
immunosuppressive agents may be able to effectively reduce α-PEG Ab induction,81 but 
these drugs also can generate undesirable side effects and health risks that may 
contraindicate their use in patients with existing illnesses.89 Once the precise mechanisms of 
human α-PEG Ab induction are better understood, the use of drugs that specifically target 
immunological pathways related anti-PEG immunity may allow the specific suppression of 
α-PEG Ab generation while avoiding unwanted side effects.
The use of alternative stealth polymers such as chitosan, poly(carboxybetaine), poly(2-
oxazaline), XTEN peptide, and poly(glycerol) has also received growing attention.90–93 
These polymers are less ubiquitous in everyday household items and thus may not encounter 
the problem of pre-existing antibodies. Nevertheless, antibodies against various natural and 
synthetic repeating polymers have been reported,94, 95 suggesting that stealth polymers other 
than PEG may also prove immunogenic upon repeated administration in humans. In 
individuals with induced or pre-existing α-PEG Abs, the elimination of circulating α-PEG 
Abs could be achieved through selective plasmapheresis, although the use of such a 
complicated procedure clearly poses additional cost burdens and may not be warranted if 
alternative strategies to remove α-PEG Abs are available. Additionally, it may be possible to 
overwhelm PEG-specific immune responses by simply administering a much greater dose of 
the PEGylated therapeutic.36, 57, 96 Nevertheless, dosage increases will obviously be limited 
by the maximum tolerated dose and potential toxicity to various clearance organs. A 
conceptually similar but more desirable approach would be to first saturate pre-existing α-
PEG Abs with free, low molecular weight PEG. Indeed, Moghimi reported that the 
administration of free PEG and PEG-containing molecules 1–3 h prior to a second dose of 
poloxamine-modified polystyrene beads reduced the ABC of these particles in rats.97 
Further animal and human studies are needed to confirm the safety and efficacy of such a 
strategy.
ONGOING QUESTIONS REGARDING ANTI-PEG ANTIBODIES
There are many questions related the phenomenon of α-PEG Abs, particularly as it applies 
to human patients, that are of great interest to the scientific and clinical communities. While 
a full discussion of these questions is beyond the scope of this review, we wish to highlight a 
few of them below:
• How are α-PEG Abs able to specifically bind PEG polymers? Due to PEG’s 
flexible, neutral, and hydrophilic character, the precise antibody-polymer 
interactions that allow α-PEG Abs to specifically bind to such an amorphous target 
in the absence of hydrophobic and electrostatic interactions are of interest.
• What is the immunological pathway of α-PEG Ab formation in humans? The 
features of human α-PEG Ab responses (i.e., pre-existing α-PEG Abs, high 
prevalence of IgG, and memory responses to PEGylated products) suggests that the 
mechanisms underlying PEG-specific immunity may differ greatly between 
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humans and animal models currently used to study anti-PEG immunity. Due to the 
difficulty of performing mechanistic studies in humans, the use of animal models 
that more accurately recapitulate human α-PEG Ab responses are necessary to 
improve our understanding of anti-PEG immunity, including that elicited by long-
term exposure to PEG and PEG-containing products.
• What factors predispose individuals towards α-PEG Ab formation and are certain 
portions of the human population more, or less, inclined towards anti-PEG 
immunity? The majority (≥50%) of patients treated with PEGylated therapeutics do 
not appear to develop α-PEG Abs, and the reasons underlying the incongruity of 
anti-PEG immune responses remain largely unknown. Increased age and 
immunosuppressive treatments were found to be associated with reduced α-PEG 
Ab induction in response to PEG-uricase.81, 86 Further analysis of patients 
receiving PEGylated therapeutics may identify other factors that affect PEG-
specific immunity, as well as reveal additional strategies to manage α-PEG Ab 
responses.
• What is the current and likely future prevalence of pre-existing α-PEG Abs? The 
reported prevalence of α-PEG Abs varies significantly, with values ranging from as 
low as 5% to over 40%. Thus, a precise estimate of the level of α-PEG Abs in both 
the general and special populations is sorely needed. Additionally, given the 
disparity in the incidence rate between early and more recent studies, the potential 
for further increases in the prevalence of pre-existing α-PEG Abs must be explored.
• How can anti-PEG immunity be efficiently and effectively managed in a clinical 
setting? Strategies to overcome pre-existing and/or induced α-PEG Abs, including 
the administration of an excess dose of PEGylated therapeutic or prior injection of 
free PEG polymer, should be further investigated.
Conclusion
Because of its ability to significantly prolong the circulation of nanoparticles and proteins, 
as well as its presumed lack of immunogenicity, PEG has been widely used to modify 
various therapeutic agents. However, a growing body of evidence indicates that potent and 
specific antibody responses can be generated against the PEG polymer, and α-PEG Ab 
induction can lead to substantial reductions in the circulation half-life and therapeutic 
efficacy of PEGylated drugs in both animal models and humans. In light of the relatively 
high prevalence of pre-existing and induced α-PEG Ab responses observed in clinical 
studies, PEG-specific immunity will likely pose a major challenge to the increasing number 
of PEGylated therapeutics used in the clinic. An improved understanding of the precise 
means by which α-PEG Abs develop and are able to bind to the polymer are needed, as are 
strategies to overcome the challenge of PEG-specific immunity.
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A) The conformation adopted by PEG chains at various grafting densities. At low grafting 
densities (RF/D ≤ 1), the PEG chains adopt a diffuse “mushroom” conformation. At higher 
densities, the PEG chains are increasingly able to repel opsonization and cell uptake as they 
transition into a more extended “brush” conformation (RF/D > 1) and eventually reach a 
“dense brush” regime (RF/D > 2.8). B) Uptake of PEG5k-grafted gold nanoparticles by 
mouse J774A.1 macrophage-like cells. A PEG5k density of 0.16 PEG/nm2 corresponds to 
brush conformation; all other PEG densities correspond to dense brush conformation. C) 
Qualitative analysis of the serum proteins adsorbed onto 30 nm gold nanoparticles modified 
with varying amounts of PEG5k. A PEG5k density of 0.24 PEG/nm2 corresponds to brush 
conformation; all other PEG densities correspond to dense brush conformation. D) Phase 
diagram mapping polymeric nanoparticle uptake by human THP-1 macrophage-like cells as 
a function of PEG length (MW) and coating density (PEG groups/nm2). The mushroom, 
brush, and dense brush conformations are indicated in dark gray, gray, and white, 
respectively, and the transitions between the mushroom-brush and brush-dense brush 
conformations are indicated by the dashed and dotted lines, respectively. E) Blood 
circulation profiles, as observed by intravital microscopy, of 100 nm unmodified (COOH) 
and PEG5k-grafted polystyrene nanoparticles. Panels B and C were reprinted with 
permission from Ref 26 (copyright 2012 ACS), and panels A, D, and E were adapted with 
permission from Ref 25 (copyright 2014 ACS).
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A) Amount of 99mTc-labeled PEGylated liposomes remaining in circulation after i.v. 
administration in rats quantified by scintigraphic image analysis. (●) indicates the first dose, 
and (○) indicates the second dose given 7 days later. B) Tissue biodistribution of 99mTc-
labeled PEGylated liposomes in rats for the initial injection (control) and for second doses 
given after 7, 14, 21, or 28 days. *p < 0.05, **p < 0.01. C) PEG-specific antibodies 
responses after an initial injection of PEGylated liposomes (0.001 μmol/kg) in rats, as 
determined using ELISA. *p < 0.05, ***p < 0.005. D) PEG-specific antibodies responses 
after an initial injection of PEGylated liposomes (100 μg/animal) in mice, as determined 
using ELISA. Panels A and B were reprinted from Ref 7; panel C was reprinted from Ref 39 
with permission from Elsevier; and panel D was reprinted from Ref 41 with permission from 
Elsevier.
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Proposed type-2 T-cell independent (TI-2) response mechanism for the formation of α-PEG 
Abs and the ABC effect. Splenic B cells are stimulated by an initial dose of PEGylated 
therapeutic and produce α-PEG IgM. These antibodies then associate with subsequent doses 
of PEGylated systems and activate complement proteins, which then opsonize PEGylated 
system and lead to its eventual clearance through hepatic MPS cells. Reprinted from Ref 8 
by permission from Macmillan Publishers Ltd.
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Anti-PEG IgM vs. asparaginase (ASNase) activity for patients treated with A) PEG-ASNase 
and B) ASNase. Flow cytometry was used to detect α-PEG Abs bound to PEG hydrogel 
(TentaGel-OH) particles. C) Mean serum uric acid (sUA) levels in patients receiving 
biweekly i.v. infusions of PEG-uricase. Normal sUA levels are typically defined as ≤6 
mg/dL (indicated by gray dashed line). D) Mean α-PEG Ab titers in patients receiving 
biweekly i.v. infusions of PEG-uricase. Panels A and B were reprinted from Ref 82, and 
panels C and D were modified from Ref 86.
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A) Direct and B) competitive enzyme-linked immunosorbent assays (ELISAs) should be 
used in combination to determine the PEG-specificity of Ab responses induced after 
treatment with a PEGylated agent (PEG-Ag1), as well as pre-existing α-PEG Abs. In direct 
ELISAs, PEG specificity can be confirmed by the cross-reactivity of α-PEG Abs to plates 
coated with pure PEG polymers (see A4) or other PEGylated materials (see A3). In 
competitive ELISAs, PEG specificity can be confirmed via the inhibition of α-PEG Ab 
binding by increasing concentrations of free PEG (see B4) or other PEGylated materials (see 
B3). Additionally, α-PEG Abs should not directly bind to non-PEGylated treatment agents 
(see A1) nor be competitively inhibited in their presence (see B1).
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